Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;7(11):e49574.
doi: 10.1371/journal.pone.0049574. Epub 2012 Nov 19.

A metal-based inhibitor of NEDD8-activating enzyme

Affiliations

A metal-based inhibitor of NEDD8-activating enzyme

Hai-Jing Zhong et al. PLoS One. 2012.

Abstract

A cyclometallated rhodium(III) complex [Rh(ppy)(2)(dppz)](+) (1) (where ppy=2-phenylpyridine and dppz=dipyrido[3,2-a:2',3'-c]phenazine dipyridophenazine) has been prepared and identified as an inhibitor of NEDD8-activating enzyme (NAE). The complex inhibited NAE activity in cell-free and cell-based assays, and suppressed the CRL-regulated substrate degradation and NF-κB activation in human cancer cells with potency comparable to known NAE inhibitor MLN4924. Molecular modeling analysis suggested that the overall binding mode of 1 within the binding pocket of the APPBP1/UBA3 heterodimer resembled that for MLN4924. Complex 1 is the first metal complex reported to suppress the NEDDylation pathway via inhibition of the NEDD8-activating enzyme.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Chemical structures of MLN4924, [Rh(ppy)2(dppz)]+ (1) and Rh(III) analogues (2–4).
Figure 2
Figure 2. Complex 1 inhibits NAE activity in a dose-dependent manner.
Western blots show dose-dependent inhibition of a) Ubc-12-NEDD8 formation in a cell-free system and b) cellular Ubc12-NEDD8 levels by 1. MLN4924 was included for comparison.
Figure 3
Figure 3. Dose-dependent inhibition of IκBα degradation by 1.
Caco-2 cells were pre-incubated with indicated concentrations of 1 for 16 hours and then stimulated with 5 ng/ml of TNF-α at indicated time intervals. Whole cell lysates were analyzed by Western blot using anti-IκBα antibody. Densitometry estimates of IκBα levels normalized with GAPDH are shown under each lane. b) Caco-2 cells were treated with 1 or MLN4924 for 16 h. The cell lysates were immunoblotted to analyse the level of CRL substrate p27.
Figure 4
Figure 4. Complex 1 suppresses NAE-regulated NF-κB-dependent luciferase reporter gene expression in a dose-dependent manner.
Caco-2 cells were transfected with the NF-κB-dependent luciferase reporter p3EnhConA-Luc gene, treated with 1 for 16 hours, and then stimulated with 5 ng/ml of TNF-α for 3 hours. Luciferase expression was measured and normalized with β-galactosidase activity. Results are expressed as fold change compared to TNF-α stimulation alone and the errors bar show the standard derivation of triplicate results. MLN4924 was included for comparison.
Figure 5
Figure 5. Low-energy binding conformations of a) 1, b) MLN4924 and c) both 1 and ATP bound to NAE heterodimer generated by virtual ligand docking.
Proteins APPBP1 (blue), UBA3 (purple) and NEDD8 (yellow) are displayed in ribbon form. Small molecules are depicted as a ball-and-stick model showing showing carbon (yellow), hydrogen (grey), oxygen (red), nitrogen (blue), phosphorus (orange) and sulfur (green). Non-polar hydrogens were not shown.

Similar articles

Cited by

References

    1. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307–320. - PubMed
    1. Hartinger CG, Dyson PJ (2009) Bioorganometallic chemistry-from teaching paradigms to medicinal applications. Chem Soc Rev 38: 391–401. - PubMed
    1. Meggers E (2009) Targeting proteins with metal complexes. Chem Commun: 1001−1010. - PubMed
    1. Klein AV, Hambley TW (2009) Platinum Drug Distribution in Cancer Cells and Tumors. Chem Rev 109: 4911–4920. - PubMed
    1. Nobili S, Mini E, Landini I, Gabbiani C, Casini A, et al. (2010) Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med Res Rev 30: 550–580. - PubMed

Publication types

MeSH terms